[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 21 of about 21
1. Osaka S, Sugita H, Osaka E, Yoshida Y, Ryu J: Surgical management of malignant soft tissue tumours in patients aged 65 years or older. J Orthop Surg (Hong Kong); 2003 Jun;11(1):28-33
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgical management of malignant soft tissue tumours in patients aged 65 years or older.
  • OBJECTIVE: With the aim to determine the most effective treatment for primary malignant musculoskeletal tumours in patients aged 65 years or older, we reviewed cases of low- and high-grade neoplasms, surgical margins, surgical methods, and the prognoses of elderly and aged patients at our institution.
  • METHODS: Records of 25 patients aged 65 years or older who had malignant soft tissue tumours from December 1986 to February 1997 were reviewed.
  • As adjuvant therapy, radiotherapy was used in 5 cases and chemotherapy in 3.
  • [MeSH-major] Histiocytoma, Benign Fibrous / surgery. Neoplasm Recurrence, Local / surgery. Orthopedic Procedures. Sarcoma / surgery. Soft Tissue Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12810968.001).
  • [ISSN] 1022-5536
  • [Journal-full-title] Journal of orthopaedic surgery (Hong Kong)
  • [ISO-abbreviation] J Orthop Surg (Hong Kong)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


2. Scotlandi K, Manara MC, Nicoletti G, Lollini PL, Lukas S, Benini S, Croci S, Perdichizzi S, Zambelli D, Serra M, García-Echeverría C, Hofmann F, Picci P: Antitumor activity of the insulin-like growth factor-I receptor kinase inhibitor NVP-AEW541 in musculoskeletal tumors. Cancer Res; 2005 May 1;65(9):3868-76
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Antitumor activity of the insulin-like growth factor-I receptor kinase inhibitor NVP-AEW541 in musculoskeletal tumors.
  • Identification of new drugs is strongly needed for sarcomas.
  • Insulin-like growth factor-I receptor (IGF-IR) was found to provide a major contribution to the malignant behavior of these tumors, therefore representing a very promising therapeutic target.
  • In this study, we analyzed the therapeutic potential of a novel kinase inhibitor of IGF-IR, NVP-AEW541, in Ewing's sarcoma, osteosarcoma, and rhabdomyosarcoma, the three most frequent solid tumors in children and adolescents.
  • Ewing's sarcoma cells were generally found to be more sensitive to the effects of this drug compared with rhabdomyosarcoma and osteosarcoma, in agreement with the high dependency of this neoplasm to IGF-IR signaling.
  • Accordingly, combined treatment with NVP-AEW541 and vincristine significantly inhibited tumor growth of Ewing's sarcoma xenografts in nude mice.
  • Therefore, results encourage inclusion of this drug especially in the treatment of patients with Ewing's sarcoma.
  • For the broadest applicability and best efficacy in sarcomas, NVP-AEW541 may be combined with vincristine, actinomycin D, and ifosfamide, three major drugs in the treatment of sarcomas.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / pharmacology. Pyrimidines / pharmacology. Pyrroles / pharmacology. Receptor, IGF Type 1 / antagonists & inhibitors. Sarcoma / drug therapy
  • [MeSH-minor] Apoptosis / drug effects. Apoptosis / physiology. Bone Neoplasms / drug therapy. Bone Neoplasms / enzymology. Cell Cycle / drug effects. Cell Cycle / physiology. Cell Growth Processes / drug effects. Cell Growth Processes / physiology. Cell Line, Tumor. Drug Screening Assays, Antitumor. Humans. Osteosarcoma / drug therapy. Osteosarcoma / enzymology. Rhabdomyosarcoma / drug therapy. Rhabdomyosarcoma / enzymology. Sarcoma, Ewing / drug therapy. Sarcoma, Ewing / enzymology. Signal Transduction / drug effects. Signal Transduction / physiology. Vincristine / administration & dosage

  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • Hazardous Substances Data Bank. VINCRISTINE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15867386.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / NVP-AEW541; 0 / Pyrimidines; 0 / Pyrroles; 5J49Q6B70F / Vincristine; EC 2.7.10.1 / Receptor, IGF Type 1
  •  go-up   go-down


3. Kopecek J, Kopecková P: HPMA copolymers: origins, early developments, present, and future. Adv Drug Deliv Rev; 2010 Feb 17;62(2):122-49
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The overview covers the discovery of N-(2-hydroxypropyl)methacrylamide (HPMA) copolymers, initial studies on their synthesis, evaluation of biological properties, and explorations of their potential as carriers of biologically active compounds in general and anticancer drugs in particular.
  • The focus is on the research in the authors' laboratory - the development of macromolecular therapeutics for the treatment of cancer and musculoskeletal diseases.
  • Finally, suggestions for the design of second-generation macromolecular therapeutics are portrayed.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 Elsevier B.V. All rights reserved.
  • [Cites] J Control Release. 1998 Apr 30;53(1-3):25-37 [9741911.001]
  • [Cites] Bioconjug Chem. 1998 Nov-Dec;9(6):793-804 [9815174.001]
  • [Cites] Clin Cancer Res. 1999 Jan;5(1):83-94 [9918206.001]
  • [Cites] Nat Biotechnol. 1999 Jan;17(1):94-5 [9920278.001]
  • [Cites] Nature. 1999 Feb 4;397(6718):417-20 [9989405.001]
  • [Cites] J Control Release. 1999 May 20;59(2):133-48 [10332049.001]
  • [Cites] Int J Oncol. 1999 Jul;15(1):5-16 [10375588.001]
  • [Cites] Nat Biotechnol. 1999 Nov;17(11):1101-4 [10545917.001]
  • [Cites] Bioconjug Chem. 2000 Jan-Feb;11(1):3-7 [10639078.001]
  • [Cites] Int J Cancer. 2000 Apr 1;86(1):108-17 [10728603.001]
  • [Cites] Clin Cancer Res. 2000 Mar;6(3):1008-15 [10741728.001]
  • [Cites] J Clin Oncol. 2002 Mar 15;20(6):1668-76 [11896118.001]
  • [Cites] Leukemia. 2002 Apr;16(4):455-62 [11960322.001]
  • [Cites] J Control Release. 2002 May 17;81(1-2):101-11 [11992683.001]
  • [Cites] Adv Drug Deliv Rev. 2002 Sep 13;54(5):653-74 [12204597.001]
  • [Cites] Adv Drug Deliv Rev. 2002 Sep 13;54(5):715-58 [12204600.001]
  • [Cites] Bioconjug Chem. 2002 Sep-Oct;13(5):975-84 [12236779.001]
  • [Cites] Pharm Res. 2008 Dec;25(12):2889-95 [18758923.001]
  • [Cites] Trends Biotechnol. 2009 Jan;27(1):11-7 [19022512.001]
  • [Cites] Bioconjug Chem. 2009 Jan;20(1):129-37 [19154157.001]
  • [Cites] Macromol Biosci. 2009 Jan 9;9(1):36-44 [18855948.001]
  • [Cites] J Am Chem Soc. 2008 Nov 26;130(47):15760-1 [18980321.001]
  • [Cites] Acta Biomater. 2009 Mar;5(3):805-16 [18952513.001]
  • [Cites] PLoS One. 2009;4(4):e5233 [19381291.001]
  • [Cites] Int J Oncol. 2009 Jun;34(6):1629-36 [19424581.001]
  • [Cites] Mol Pharm. 2009 May-Jun;6(3):959-70 [19344119.001]
  • [Cites] Biomacromolecules. 2009 Aug 10;10(8):2319-27 [19591463.001]
  • [Cites] Macromol Biosci. 2009 Nov 10;9(11):1135-42 [19685500.001]
  • [Cites] J Control Release. 2009 Dec 16;140(3):230-6 [19527757.001]
  • [Cites] Angew Chem Int Ed Engl. 2010 Feb 15;49(8):1451-5 [20101660.001]
  • [Cites] J Control Release. 2010 Apr 2;143(1):71-9 [20043962.001]
  • [Cites] Biomacromolecules. 2009 Jul 13;10(7):1704-14 [21197960.001]
  • [Cites] Br J Cancer. 2002 Sep 9;87(6):608-14 [12237769.001]
  • [Cites] Nucleic Acids Res. 2001 May 1;29(9):1852-63 [11328868.001]
  • [Cites] Bioconjug Chem. 2003 Jan-Feb;14(1):44-50 [12526691.001]
  • [Cites] Nat Rev Drug Discov. 2003 Mar;2(3):214-21 [12612647.001]
  • [Cites] Pharm Res. 2003 Mar;20(3):360-7 [12669954.001]
  • [Cites] Nat Rev Drug Discov. 2003 May;2(5):347-60 [12750738.001]
  • [Cites] Pharm Res. 2003 May;20(5):728-37 [12751627.001]
  • [Cites] Photochem Photobiol. 2003 Jun;77(6):645-52 [12870851.001]
  • [Cites] Bioconjug Chem. 2003 Sep-Oct;14(5):853-9 [13129387.001]
  • [Cites] Eur J Pharm Sci. 2003 Sep;20(1):1-16 [13678788.001]
  • [Cites] Cancer Res. 2003 Nov 15;63(22):7876-82 [14633716.001]
  • [Cites] Polim Med. 1977;7(3):191-221 [593972.001]
  • [Cites] Biochem Biophys Res Commun. 1980 May 14;94(1):284-90 [7387696.001]
  • [Cites] Folia Biol (Praha). 1980;26(5):304-11 [6449390.001]
  • [Cites] Biomaterials. 1980 Oct;1(4):199-204 [7470574.001]
  • [Cites] Annu Rev Biochem. 1982;51:531-54 [6287920.001]
  • [Cites] Biomaterials. 1982 Jul;3(3):150-4 [7115858.001]
  • [Cites] Biochim Biophys Acta. 1983 Feb 22;755(3):518-21 [6824743.001]
  • [Cites] Biosci Rep. 1982 Dec;2(12):1041-6 [6762230.001]
  • [Cites] Biomaterials. 1983 Jan;4(1):44-8 [6301566.001]
  • [Cites] Folia Microbiol (Praha). 1983;28(3):217-27 [6873772.001]
  • [Cites] Biomaterials. 1984 Jan;5(1):19-25 [6375745.001]
  • [Cites] Biomaterials. 1984 May;5(3):143-8 [6733215.001]
  • [Cites] Biomaterials. 1985 Jan;6(1):45-8 [3971018.001]
  • [Cites] Biochim Biophys Acta. 1986 Jan 15;880(1):62-71 [3942780.001]
  • [Cites] J Chromatogr. 1986 Apr 11;376:221-33 [3519635.001]
  • [Cites] Folia Biol (Praha). 1986;32(2):91-102 [3721017.001]
  • [Cites] Cancer Res. 1986 Dec;46(12 Pt 1):6387-92 [2946403.001]
  • [Cites] J Biomed Mater Res. 1987 Nov;21(11):1341-58 [3680316.001]
  • [Cites] Clin Immunol Immunopathol. 1988 Jan;46(1):100-14 [2891460.001]
  • [Cites] J Natl Cancer Inst. 1989 Apr 19;81(8):570-6 [2649688.001]
  • [Cites] Pharm Res. 1990 Apr;7(4):339-46 [1694582.001]
  • [Cites] J Biomater Sci Polym Ed. 1990;1(4):261-78 [1703786.001]
  • [Cites] Br J Cancer. 1991 Apr;63(4):546-9 [1827030.001]
  • [Cites] Bioconjug Chem. 1992 Sep-Oct;3(5):351-62 [1420435.001]
  • [Cites] Bioconjug Chem. 1993 Jul-Aug;4(4):290-5 [8110229.001]
  • [Cites] J Biomater Sci Polym Ed. 1994;5(4):303-24 [8025029.001]
  • [Cites] Cancer Res. 1994 Aug 15;54(16):4313-20 [8044778.001]
  • [Cites] Pharm Res. 1995 May;12(5):663-8 [7479550.001]
  • [Cites] Cell. 1995 Dec 15;83(6):835-9 [8521507.001]
  • [Cites] Eur J Cancer. 1996 Jun;32A(6):927-44 [8763334.001]
  • [Cites] Eur J Cancer. 1996 Jun;32A(6):945-57 [8763335.001]
  • [Cites] Cancer Res. 1996 Sep 1;56(17):3980-5 [8752167.001]
  • [Cites] J Drug Target. 1996;3(5):357-73 [8866655.001]
  • [Cites] J Cell Sci. 1997 Dec;110 ( Pt 24):3065-70 [9365276.001]
  • [Cites] Int J Cancer. 1998 Feb 9;75(4):600-8 [9466663.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Apr 14;95(8):4607-12 [9539785.001]
  • [Cites] Jpn J Cancer Res. 1998 Mar;89(3):307-14 [9600125.001]
  • [Cites] Nature. 1998 May 28;393(6683):392-6 [9620806.001]
  • [Cites] Br J Cancer. 1999 Sep;81(1):99-107 [10487619.001]
  • [Cites] Pharm Res. 2004 Oct;21(10):1741-9 [15553217.001]
  • [Cites] Adv Drug Deliv Rev. 2005 Feb 28;57(4):609-36 [15722167.001]
  • [Cites] Mol Pharm. 2004 May-Jun;1(3):174-82 [15981920.001]
  • [Cites] Biomacromolecules. 2005 Jul-Aug;6(4):1846-50 [16004419.001]
  • [Cites] J Nucl Med. 2005 Sep;46(9):1552-60 [16157540.001]
  • [Cites] Biochemistry. 2005 Oct 25;44(42):13664-72 [16229456.001]
  • [Cites] Biomaterials. 2006 Mar;27(7):1140-51 [16098577.001]
  • [Cites] J Control Release. 2006 Jan 10;110(2):323-31 [16290118.001]
  • [Cites] Bioconjug Chem. 2006 Mar-Apr;17(2):514-23 [16536485.001]
  • [Cites] Biomacromolecules. 2006 Apr;7(4):1187-95 [16602737.001]
  • [Cites] Clin Cancer Res. 2004 May 15;10(10):3386-95 [15161693.001]
  • [Cites] Antibiotiki. 1965 Aug;10(8):701-6 [5887624.001]
  • [Cites] Antibiotiki. 1966 Sep;11(9):767-70 [4968207.001]
  • [Cites] J Biomed Mater Res. 1971 May;5(3):197-205 [5560996.001]
  • [Cites] J Biomed Mater Res. 1971 Sep;5(5):447-58 [5120385.001]
  • [Cites] J Biomed Mater Res. 1973 Jan;7(1):111-21 [4691154.001]
  • [Cites] J Biomed Mater Res. 1973 Jan;7(1):123-36 [4691155.001]
  • [Cites] J Biomed Mater Res. 1973 Mar;7(2):179-91 [4267380.001]
  • [Cites] J Biomed Mater Res. 1974 Mar;8(2):155-61 [4133414.001]
  • [Cites] Biochem Pharmacol. 1974 Sep 15;23(18):2495-531 [4606365.001]
  • [Cites] Nature. 1975 Mar 13;254(5496):109-14 [1117994.001]
  • [Cites] J Biomed Mater Res. 1975 Nov;9(6):675-85 [1184613.001]
  • [Cites] Polim Med. 1974;4(2):109-17 [4468387.001]
  • [Cites] J Biomed Mater Res. 1976 Nov;10(6):953-63 [993230.001]
  • [Cites] J Biol Chem. 1977 Jun 10;252(11):3582-6 [16907.001]
  • [Cites] Eur J Pharm Biopharm. 2000 Jul;50(1):61-81 [10840193.001]
  • [Cites] J Biomed Mater Res. 2000 Sep 5;51(3):329-42 [10880074.001]
  • [Cites] Bioconjug Chem. 2000 Sep-Oct;11(5):734-40 [10995218.001]
  • [Cites] J Control Release. 2000 Oct 3;69(1):185-96 [11018556.001]
  • [Cites] Eur J Cancer. 2001 Jan;37(1):131-9 [11165140.001]
  • [Cites] J Control Release. 2001 Apr 28;71(3):227-37 [11295216.001]
  • [Cites] Anticancer Drugs. 2001 Apr;12(4):315-23 [11335787.001]
  • [Cites] J Control Release. 2001 Jul 6;74(1-3):203-11 [11489496.001]
  • [Cites] J Control Release. 2001 Jul 6;74(1-3):249-53 [11489502.001]
  • [Cites] J Control Release. 2001 Aug 10;75(3):365-79 [11489323.001]
  • [Cites] Bioorg Med Chem Lett. 2001 Aug 20;11(16):2089-91 [11514145.001]
  • [Cites] J Drug Target. 2001 Apr;9(2):85-94 [11697110.001]
  • [Cites] Nat Biotechnol. 2001 Dec;19(12):1155-61 [11731785.001]
  • [Cites] Mol Biol Cell. 2002 Feb;13(2):425-34 [11854401.001]
  • [Cites] Pharm Res. 2002 Feb;19(2):115-23 [11883637.001]
  • [Cites] Mol Pharm. 2006 May-Jun;3(3):351-61 [16749867.001]
  • [Cites] Nat Chem Biol. 2006 Jul;2(7):381-9 [16767086.001]
  • [Cites] Nat Chem Biol. 2006 Jul;2(7):351-2 [16783336.001]
  • [Cites] Biomacromolecules. 2006 Aug;7(8):2347-56 [16903681.001]
  • [Cites] Science. 2006 Nov 3;314(5800):815-7 [17082456.001]
  • [Cites] J Drug Target. 2006 Jul;14(6):425-35 [17092842.001]
  • [Cites] Biomacromolecules. 2006 Nov;7(11):3037-46 [17096529.001]
  • [Cites] Mol Pharm. 2006 Nov-Dec;3(6):717-25 [17140259.001]
  • [Cites] J Control Release. 2007 Feb 12;117(2):179-85 [17150276.001]
  • [Cites] J Drug Target. 2007 Aug-Sep;15(7-8):465-74 [17671893.001]
  • [Cites] Bioconjug Chem. 2007 Sep-Oct;18(5):1375-8 [17705416.001]
  • [Cites] Biomaterials. 2007 Dec;28(34):5185-92 [17697712.001]
  • [Cites] J Control Release. 2007 Dec 4;124(1-2):6-10 [17869367.001]
  • [Cites] Pharm Res. 2008 Jan;25(1):218-26 [17929146.001]
  • [Cites] Biomacromolecules. 2008 Feb;9(2):510-7 [18208316.001]
  • [Cites] Int J Pharm. 2008 Mar 3;351(1-2):259-70 [18029122.001]
  • [Cites] Biomacromolecules. 2008 Mar;9(3):919-26 [18288801.001]
  • [Cites] Macromol Biosci. 2008 May 13;8(5):375-83 [18215003.001]
  • [Cites] Mol Pharm. 2008 Jul-Aug;5(4):548-58 [18505266.001]
  • [Cites] Macromol Biosci. 2008 Jul 7;8(7):599-605 [18401866.001]
  • [Cites] Mol Pharm. 2008 Sep-Oct;5(5):696-709 [18729468.001]
  • [Cites] Mol Pharm. 2008 Sep-Oct;5(5):776-86 [18767867.001]
  • [Cites] Pharm Res. 2008 Dec;25(12):2910-9 [18649124.001]
  • [Cites] J Control Release. 1999 Aug 5;60(2-3):321-32 [10425337.001]
  • [Cites] Pharm Res. 1999 Jul;16(7):986-96 [10450921.001]
  • [Cites] Pharm Res. 1999 Jul;16(7):1010-9 [10450924.001]
  • [Cites] J Control Release. 1999 Aug 27;61(1-2):145-57 [10469911.001]
  • (PMID = 19919846.001).
  • [ISSN] 1872-8294
  • [Journal-full-title] Advanced drug delivery reviews
  • [ISO-abbreviation] Adv. Drug Deliv. Rev.
  • [Language] ENG
  • [Grant] United States / NIBIB NIH HHS / EB / R01 EB005288; United States / NIGMS NIH HHS / GM / GM069847-06; United States / NIBIB NIH HHS / EB / R01 EB005288-04; United States / NCI NIH HHS / CA / CA132831; United States / NCI NIH HHS / CA / R01 CA051578-17; United States / FIC NIH HHS / TW / R03 TW006260-03; United States / NIGMS NIH HHS / GM / R01 GM069847-06; United States / NIBIB NIH HHS / EB / EB005288; United States / FIC NIH HHS / TW / R03 TW006260; United States / FIC NIH HHS / TW / TW006260-03; United States / NCI NIH HHS / CA / R01 CA132831-02; United States / NCI NIH HHS / CA / R01 CA132831; United States / FIC NIH HHS / TW / TW006260; United States / NIGMS NIH HHS / GM / GM069847; United States / NCI NIH HHS / CA / CA51578; United States / NCI NIH HHS / CA / CA132831-02; United States / NIGMS NIH HHS / GM / R01 GM069847; United States / NCI NIH HHS / CA / R01 CA051578; United States / NCI NIH HHS / CA / CA051578-17
  • [Publication-type] Comparative Study; Historical Article; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Acrylamides; 0 / Antineoplastic Agents; 0 / Polymers; 21442-01-3 / N-(2-hydroxypropyl)methacrylamide
  • [Other-IDs] NLM/ NIHMS159442; NLM/ PMC2836498
  •  go-up   go-down


Advertisement
4. Ludwig K: [Musculoskeletal lymphomas]. Radiologe; 2002 Dec;42(12):988-92
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Musculoskeletal lymphomas].
  • Their differential diagnosis includes -- depending on the patient's age -- Ewing's sarcoma,malignant fibrous histiocytoma,metastases of small cell tumors and osteomyelitis.Further differential diagnoses are the peripheral primitive neuroectodermal tumor (PNET), osteosarcoma, eosinophilic granuloma and fibrosarcoma.
  • Treatment of primary non-Hodgkin's lymphomas uses combinations of chemotherapy and radiation therapy.
  • Operative treatment is reserved for the treatment of complications.
  • [MeSH-major] Bone Neoplasms / diagnosis. Hodgkin Disease / diagnosis. Lymphoma, Non-Hodgkin / diagnosis. Magnetic Resonance Imaging. Muscle Neoplasms / diagnosis. Tomography, X-Ray Computed
  • [MeSH-minor] Bone and Bones / pathology. Humans. Muscle, Skeletal / pathology. Neoplasm Staging. Prognosis. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12486552.001).
  • [ISSN] 0033-832X
  • [Journal-full-title] Der Radiologe
  • [ISO-abbreviation] Radiologe
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 0
  •  go-up   go-down


5. Veth R, van Hoesel R, Pruszczynski M, Hoogenhout J, Schreuder B, Wobbes T: Limb salvage in musculoskeletal oncology. Lancet Oncol; 2003 Jun;4(6):343-50
MedlinePlus Health Information. consumer health - Bone Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Limb salvage in musculoskeletal oncology.
  • Since the early 1970s, substantial progress in dealing with musculoskeletal tumours has been made, with improvements in surgical skills, radiology, chemotherapy, pathology, and radiotherapy.
  • Nowadays, 70-85% of all malignant tumours are treated by limb salvage, without compromising the oncological result.
  • After many years, the functional result that may be achieved with a limb-saving procedure is becoming clear.
  • In the future, the co-operating disciplines should strive for better survival of these patients, for which the development of new chemotherapeutic drugs is especially needed.
  • [MeSH-major] Bone Neoplasms / therapy. Limb Salvage / methods. Muscle Neoplasms / therapy
  • [MeSH-minor] Combined Modality Therapy. Drug-Related Side Effects and Adverse Reactions. Humans. Neoplasm Staging. Postoperative Complications. Prostheses and Implants / adverse effects. Radiotherapy / adverse effects

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12788406.001).
  • [ISSN] 1470-2045
  • [Journal-full-title] The Lancet. Oncology
  • [ISO-abbreviation] Lancet Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 71
  •  go-up   go-down


6. Bacci G, Ferrari C, Longhi A, Ferrari S, Forni C, Bacchini P, Palmerini E, Briccoli A, Pignotti E, Balladelli A, Picci P: Second malignant neoplasm in patients with osteosarcoma of the extremities treated with adjuvant and neoadjuvant chemotherapy. J Pediatr Hematol Oncol; 2006 Dec;28(12):774-80
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Second malignant neoplasm in patients with osteosarcoma of the extremities treated with adjuvant and neoadjuvant chemotherapy.
  • We evaluated the rate of second malignancies in 1205 patients with osteosarcoma of the extremity treated at our Institution with different protocols of adjuvant and neoadjuvant chemotherapy.
  • Twenty-six patients (2.15%) developed a second malignant neoplasm at a median of 7.6 years (1 to 25 y) after primary osteosarcoma treatment.
  • Of these, 2 developed a third cancer which were not considered in the series.
  • Second neoplasms were leukemia (10), breast (7), lung (2), kidney (2), central nervous system cancer (2), soft tissue (1), parotid (1), and colon (1).
  • Ten of these 26 patients are disease free at a median of 7.7 years (range 1 to 15 y) after the last treatment.
  • Our study showed that the risk of second neoplasm within 15 years increased and then leveled off and that although secondary solid tumors could be explained as unrelated cases, leukemias seem to be over represented.
  • [MeSH-minor] Adolescent. Adult. Chemotherapy, Adjuvant / methods. Child. Child, Preschool. Disease-Free Survival. Female. Humans. Incidence. Infant. Male. Neoplasms / drug therapy. Neoplasms / epidemiology. Retrospective Studies. Risk Factors. Sex Factors. Time Factors

  • Genetic Alliance. consumer health - Osteosarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17164644.001).
  • [ISSN] 1077-4114
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


7. Kawai A, Hosono A, Nakayama R, Matsumine A, Matsumoto S, Ueda T, Tsuchiya H, Beppu Y, Morioka H, Yabe H, Japanese Musculoskeletal Oncology Group: Clear cell sarcoma of tendons and aponeuroses: a study of 75 patients. Cancer; 2007 Jan 1;109(1):109-16

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Clear cell sarcoma (CCS) of tendons and aponeuroses (malignant melanoma of soft parts) is a rare melanocytic soft tissue sarcoma.
  • The objective of this study was to determine the clinical features, prognostic factors, and optimal treatment policy for patients with this rare disease.
  • METHODS: Seventy-five consecutive patients with histologically confirmed CCS who received treatment between 1980 and 2004 were analyzed retrospectively.
  • Seventy-one patients underwent surgical excision, and 56 patients received chemotherapy.
  • Sixteen patients developed local recurrences, and 52 patients developed metastasis.
  • Among the 52 patients who presented with localized disease, sex (P = .023), tumor size (P = .002), tumor depth (P = .011), TNM classification (P = .004), and chemotherapy (P = .032) were identified as significant prognostic factors.
  • The role of chemotherapy for CCS should be investigated further.
  • [MeSH-major] Sarcoma, Clear Cell / pathology. Sarcoma, Clear Cell / therapy. Soft Tissue Neoplasms / pathology. Soft Tissue Neoplasms / therapy. Tendons
  • [MeSH-minor] Adult. Female. Humans. Male. Melanoma / mortality. Melanoma / pathology. Melanoma / therapy. Multivariate Analysis. Neoplasm Metastasis. Neoplasm Recurrence, Local. Prognosis. Retrospective Studies. Survival Rate. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2006 American Cancer Society.
  • (PMID = 17133413.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


8. Abu-Shakra M, Buskila D, Ehrenfeld M, Conrad K, Shoenfeld Y: Cancer and autoimmunity: autoimmune and rheumatic features in patients with malignancies. Ann Rheum Dis; 2001 May;60(5):433-41
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cancer and autoimmunity: autoimmune and rheumatic features in patients with malignancies.
  • RESULTS: Patients with malignant diseases may develop autoimmune phenomena and rheumatic diseases as a result of (a) generation of autoantibodies against various autoantigens, including oncoproteins (P185, 1-myc, c-myc, c-myb), tumour suppression genes (P53), proliferation associated antigens (cyclin A, B1, D1, E; CENP-F; CDK, U3-RNP), onconeural antigens (Hu, Yo, Ri, Tr), cancer/testis antigens (MAGE, GAGE, BAGE, SSX, ESO, SCP, CT7), and rheumatic disease associated antigens (RNP, Sm).
  • Anti-oncoprotein and anti-tumour suppression gene antigens are detected before the diagnosis of the cancer or in the early stages of the malignant disease, suggesting a potential diagnostic or prognostic role.
  • Anti-onconeural antibodies are pathogenic and are associated with specific clinical neurological syndromes (anti-Hu syndrome and others). (b) Paraneoplastic syndromes, a wide range of clinical syndromes, including classic autoimmune rheumatic diseases that develop among patients with cancer. (c) Rheumatism after chemotherapy, a clinical entity characterised by the development of musculoskeletal symptoms after combination chemotherapy for malignancy.
  • [MeSH-minor] Antibodies, Antinuclear / immunology. Antigens, Neoplasm / immunology. Antineoplastic Combined Chemotherapy Protocols / adverse effects. Female. Hematologic Neoplasms / drug therapy. Hematologic Neoplasms / immunology. Humans. Interferons / adverse effects. Male. Oncogene Proteins / immunology. Proliferating Cell Nuclear Antigen / immunology

  • MedlinePlus Health Information. consumer health - Autoimmune Diseases.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Invest Med. 1997 Oct;20(5):308-19 [9336656.001]
  • [Cites] J Clin Oncol. 1997 Nov;15(11):3363-7 [9363867.001]
  • [Cites] J Clin Gastroenterol. 1997 Oct;25(3):535-7 [9412972.001]
  • [Cites] J Exp Med. 1998 Jan 19;187(2):265-70 [9432985.001]
  • [Cites] Neurology. 1998 Mar;50(3):652-7 [9521251.001]
  • [Cites] Oncol Rep. 1998 May-Jun;5(3):753-61 [9538189.001]
  • [Cites] Hematol Cell Ther. 1998 Feb;40(1):1-9 [9556183.001]
  • [Cites] J Exp Med. 1998 Apr 20;187(8):1163-7 [9547328.001]
  • [Cites] J Exp Med. 1998 Apr 20;187(8):1349-54 [9547346.001]
  • [Cites] Clin Cancer Res. 1995 Dec;1(12):1463-9 [9815945.001]
  • [Cites] Clin Cancer Res. 1996 Oct;2(10):1767-75 [9816128.001]
  • [Cites] Ann Neurol. 1999 Feb;45(2):162-7 [9989617.001]
  • [Cites] Eur J Cancer. 1998 Nov;34(12):1983 [10023329.001]
  • [Cites] Arthritis Rheum. 1999 Mar;42(3):569-73 [10088781.001]
  • [Cites] J Intern Med. 1999 Mar;245(3):277-86 [10205590.001]
  • [Cites] Clin Neurol Neurosurg. 1999 Sep;101(3):207-9 [10536910.001]
  • [Cites] Curr Opin Neurol. 1999 Oct;12(5):617-25 [10590899.001]
  • [Cites] Leuk Res. 2000 Jan;24(1):83-6 [10634651.001]
  • [Cites] Prog Neurobiol. 2000 Feb;60(2):181-210 [10639054.001]
  • [Cites] Cancer. 2000 Mar 15;88(6):1432-7 [10717627.001]
  • [Cites] Cancer Res. 2000 Apr 1;60(7):1777-88 [10766157.001]
  • [Cites] Clin Chem Lab Med. 2000 Feb;38(2):117-22 [10834398.001]
  • [Cites] Lupus. 1996 Aug;5(4):255-6 [8869893.001]
  • [Cites] Hepatology. 1997 Jan;25(1):75-80 [8985268.001]
  • [Cites] Curr Biol. 1997 Feb 1;7(2):144-7 [9016702.001]
  • [Cites] J Neurol. 1997 Feb;244(2):85-9 [9120501.001]
  • [Cites] J Neuroimmunol. 1997 Apr;74(1-2):55-61 [9119979.001]
  • [Cites] J Neurol Sci. 1997 Mar 20;147(1):35-42 [9094058.001]
  • [Cites] Haematologica. 1997 Jan-Feb;82(1):101-5 [9107095.001]
  • [Cites] Mol Cell Biol. 1997 Jun;17(6):3194-201 [9154818.001]
  • [Cites] Int Arch Allergy Immunol. 2000 Sep;123(1):77-91 [11014974.001]
  • [Cites] Blood. 1979 Apr;53(4):545-51 [426906.001]
  • [Cites] Postgrad Med J. 1980 Jul;56(657):513-5 [7443609.001]
  • [Cites] Ann Intern Med. 1981 Sep;95(3):288-92 [6168223.001]
  • [Cites] J Rheumatol. 1990 Nov;17(11):1458-62 [2273485.001]
  • [Cites] Int J Cancer. 1991 Mar 12;47(5):665-9 [2004847.001]
  • [Cites] Proc Natl Acad Sci U S A. 1991 Apr 15;88(8):3451-4 [2014264.001]
  • [Cites] Ann Intern Med. 1991 Aug 1;115(3):178-83 [2058872.001]
  • [Cites] J Rheumatol. 1991 Jun;18(6):809-14 [1895261.001]
  • [Cites] N Engl J Med. 1992 Feb 6;326(6):363-7 [1729618.001]
  • [Cites] Curr Opin Rheumatol. 1992 Feb;4(1):90-3 [1543670.001]
  • [Cites] Medicine (Baltimore). 1992 Mar;71(2):59-72 [1312211.001]
  • [Cites] Am J Pathol. 1992 Apr;140(4):859-70 [1314027.001]
  • [Cites] Clin Immunol Immunopathol. 1992 Oct;65(1):70-4 [1382910.001]
  • [Cites] Leuk Lymphoma. 1992 May;7(1-2):117-22 [1472921.001]
  • [Cites] N Engl J Med. 1993 Feb 25;328(8):546-51 [8381208.001]
  • [Cites] Arthritis Rheum. 1993 Apr;36(4):460-4 [8457221.001]
  • [Cites] J Clin Oncol. 1993 Apr;11(4):768-70 [8478669.001]
  • [Cites] Semin Nephrol. 1993 May;13(3):258-72 [8321926.001]
  • [Cites] Cancer Res. 1999 May 15;59(10):2470-6 [10344760.001]
  • [Cites] Biomed Pharmacother. 1999 Jun;53(5-6):242-54 [10424246.001]
  • [Cites] J Clin Oncol. 1993 Oct;11(10):2051-2 [8410132.001]
  • [Cites] Int J Cancer. 1982 Oct 15;30(4):403-8 [6292117.001]
  • [Cites] J Immunol. 1983 Jun;130(6):2496-8 [6189889.001]
  • [Cites] J Rheumatol. 1986 Dec;13(6):1167-72 [3560105.001]
  • [Cites] Brain. 1988 Jun;111 ( Pt 3):577-96 [2838124.001]
  • [Cites] Medicine (Baltimore). 1988 Jul;67(4):220-30 [3292873.001]
  • [Cites] Br J Cancer. 1988 Jun;57(6):529-34 [3044429.001]
  • [Cites] Ann Intern Med. 1990 May 1;112(9):682-98 [2110431.001]
  • [Cites] Cancer. 1990 Jun 1;65(11):2554-8 [2337872.001]
  • [Cites] J Clin Oncol. 1993 Aug;11(8):1625-6 [8336200.001]
  • [Cites] J Clin Invest. 1993 Nov;92(5):2419-26 [8227358.001]
  • [Cites] J Rheumatol. 1993 Aug;20(8):1386-7 [7901413.001]
  • [Cites] Arch Intern Med. 1994 Feb 14;154(3):334-40 [8297201.001]
  • [Cites] Br J Rheumatol. 1994 Jun;33(6):583-5 [8205409.001]
  • [Cites] J Exp Med. 1994 Jul 1;180(1):1-4 [8006576.001]
  • [Cites] J Neurobiol. 1994 Feb;25(2):143-55 [7517436.001]
  • [Cites] Int J Cancer. 1994 Aug 15;58(4):480-7 [8056443.001]
  • [Cites] Mol Biol Rep. 1994 Mar;19(2):115-24 [8072492.001]
  • [Cites] Scand J Rheumatol. 1994;23(5):291-2 [7973485.001]
  • [Cites] J Rheumatol. 1994 Oct;21(10):1855-9 [7837150.001]
  • [Cites] Biochem Biophys Res Commun. 1995 Feb 27;207(3):1029-37 [7864889.001]
  • [Cites] J Cell Biol. 1995 Aug;130(3):507-18 [7542657.001]
  • [Cites] Br J Cancer. 1995 Aug;72(2):447-51 [7640230.001]
  • [Cites] J Natl Cancer Inst. 1995 Sep 20;87(18):1400-7 [7658501.001]
  • [Cites] Nat Med. 1995 Jul;1(7):701-2 [7585154.001]
  • [Cites] J Autoimmun. 1995 Aug;8(4):575-86 [7492351.001]
  • [Cites] Arthritis Rheum. 1996 Jun;39(6):1050-4 [8651970.001]
  • [Cites] Hematol Oncol Clin North Am. 1996 Apr;10(2):345-63 [8707759.001]
  • [Cites] South Med J. 1996 Aug;89(8):810-4 [8701383.001]
  • [Cites] Immunol Lett. 1995 Dec;48(2):129-32 [8719111.001]
  • [Cites] Int J Cancer. 1996 Aug 22;69(4):283-9 [8797869.001]
  • [Cites] Am J Clin Oncol. 1997 Jun;20(3):322-6 [9167764.001]
  • [Cites] Semin Oncol. 1997 Jun;24(3):299-317 [9208886.001]
  • [Cites] Semin Oncol. 1997 Jun;24(3):318-28 [9208887.001]
  • [Cites] Semin Oncol. 1997 Jun;24(3):329-33 [9208888.001]
  • (PMID = 11302861.001).
  • [ISSN] 0003-4967
  • [Journal-full-title] Annals of the rheumatic diseases
  • [ISO-abbreviation] Ann. Rheum. Dis.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Antinuclear; 0 / Antigens, Neoplasm; 0 / Autoantibodies; 0 / Oncogene Proteins; 0 / Proliferating Cell Nuclear Antigen; 9008-11-1 / Interferons
  • [Number-of-references] 94
  • [Other-IDs] NLM/ PMC1753641
  •  go-up   go-down


9. Eyesan SU, Obalum DC, Onovo DO, Ketiku KK, Abdulkareem FB: Indications for ablative surgery in extremity musculoskeletal tumours. Nig Q J Hosp Med; 2009 Sep-Dec;19(4):206-9
MedlinePlus Health Information. consumer health - Bone Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Indications for ablative surgery in extremity musculoskeletal tumours.
  • BACKGROUND: Surgical options for treatment of extremity musculoskeletal tumours include excision [limb sparing] surgery or amputation [limb ablation].
  • Ablative surgery is for advanced extremity musculoskeletal tumours when limb salvage surgery is not feasible.
  • OBJECTIVE: To determine the indications for ablative surgery in extremity musculoskeletal tumours in our centre.
  • METHOD: This is a 6 year prospective study of patients presenting with extremity musculoskeletal tumours at National Orthopaedic Hospital Lagos.
  • Data such as age, gender, presenting complaints, anatomic location of the tumour, clinical stage, type of ablative surgery and adjuvant treatment offered, histologic type of tumour, and treatment outcome were documented.
  • RESULTS: Nineteen patients had ablative surgery as a mode of treatment.
  • Seven patients [6 males and 1 female] refused ablative surgery and voluntarily discontinued treatment.
  • Most tumours were located in the lower limb and all patients that had ablative treatment presented with stage 3 or 4 disease.
  • Six patients [31.6%] with non-malignant tumours had ablative surgery due to either late presentation or inaccurate preoperative diagnosis.
  • Adjuvant chemotherapy was prescribed for all patients.
  • CONCLUSION: Late presentation with locally advanced disease remains the dominant indication for ablative surgery in extremity musculoskeletal tumours.
  • [MeSH-major] Amputation / methods. Bone Neoplasms / surgery. Lower Extremity / surgery. Neoplasms, Bone Tissue / surgery. Upper Extremity / surgery
  • [MeSH-minor] Adolescent. Adult. Aged. Chemotherapy, Adjuvant. Child. Child, Preschool. Female. Follow-Up Studies. Hospitals, Special. Humans. Male. Middle Aged. Neoplasm Staging. Nigeria. Orthopedics. Prospective Studies. Radiotherapy, Adjuvant. Treatment Outcome. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20836332.001).
  • [ISSN] 0189-2657
  • [Journal-full-title] Nigerian quarterly journal of hospital medicine
  • [ISO-abbreviation] Nig Q J Hosp Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Nigeria
  •  go-up   go-down


10. Goto T, Okuma T, Nakada I, Hozumi T, Kondo T: [Preoperative adjuvant therapy for primary malignant bone tumors]. Gan To Kagaku Ryoho; 2007 Nov;34(11):1750-4
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Preoperative adjuvant therapy for primary malignant bone tumors].
  • In primary bone sarcomas, the efficacy of chemotherapy varies according to the histological types.
  • However, because these sarcomas are chemosensitive, their prognoses have been improved with adjuvant chemotherapy.
  • Nowadays, in highgrade bone sarcomas, especially in osteosarcoma, Ewing.s sarcoma and malignant fibrous histiocytoma of bone, adjuvant chemotherapy including neoadjuvant or preoperative chemotherapy is usually performed.
  • The purpose of the neoadjuvant chemotherapy is (I) to prevent distant metastases, (II) to reduce the size of the primary tumor and (III) to evaluate the efficacy of the chemotherapeutic agents.
  • Evaluating the efficacy of the chemotherapeutic agents in preoperative chemotherapy facilitates rational selection of postoperative chemotherapeutic agents.
  • Commonly used drugs include adriamycin, ifosfamide, cisplatin, methotrexate and vincristine in osteosarcoma, and vincristine, adriamycin, cyclophosphamide, ifosfamide, actinomycin-D and etoposide in Ewing's sarcoma.
  • In contrast, chondrosarcomas are chemoresistant, and chemotherapy is rarely performed.
  • Low-grade bone sarcomas, e. g., parosteal osteosarcoma, central low-grade osteosarcoma, are well cured only by surgical excision, and adjuvant chemotherapy is not performed for these low-grade sarcomas.
  • To enhance the efficacy of preoperative chemotherapy, various modalities have been used e. g., intraarterial infusion, caffeine-assisted chemotherapy, and local perfusion with hyperthermia.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bone Neoplasms / drug therapy
  • [MeSH-minor] Cyclophosphamide / administration & dosage. Dactinomycin / administration & dosage. Doxorubicin / administration & dosage. Drug Administration Schedule. Humans. Ifosfamide / administration & dosage. Neoadjuvant Therapy. Neoplasm Metastasis / prevention & control. Osteosarcoma / drug therapy. Osteosarcoma / surgery. Prognosis. Sarcoma, Ewing / drug therapy. Sarcoma, Ewing / surgery. Soft Tissue Neoplasms / drug therapy. Soft Tissue Neoplasms / surgery. Vincristine / administration & dosage

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. DACTINOMYCIN .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18030009.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 1CC1JFE158 / Dactinomycin; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; UM20QQM95Y / Ifosfamide; VAC protocol; VACA protocol; VAIA protocol
  •  go-up   go-down


11. Weber K, Damron TA, Frassica FJ, Sim FH: Malignant bone tumors. Instr Course Lect; 2008;57:673-88
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant bone tumors.
  • Malignant bone tumors represent a small percentage of cancers nationwide and also are much less common than malignant soft-tissue tumors.
  • The rarity of the condition makes it imperative that orthopaedic surgeons in nononcologic practices are able to recognize the symptoms that suggest a possible bony malignancy to avoid inappropriate or delayed treatment.
  • The most common primary malignant bone tumors, osteosarcoma and Ewing's sarcoma, occur in childhood.
  • The primary symptom of a patient with a malignant bone tumor is pain, which often occurs at rest or at night.
  • Knowledge of specific tumor characteristics and treatment options for osteosarcoma, Ewing's sarcoma, chondrosarcoma, malignant fibrous histiocytoma, chordoma, and adamantinoma is important.
  • Patients with osteosarcoma and resectable Ewing's sarcoma are treated with chemotherapy followed by surgical resection.
  • Secondary sarcomas can occur in previously benign bone lesions and require aggressive treatment.
  • Specific techniques are available for the resection of malignant bone tumors from the upper extremities, lower extremities, pelvis, and spine.
  • The care of patients with primary malignant bone tumors requires a multidisciplinary approach to treatment.
  • The orthopaedic oncologist is a vital member of a team composed of musculoskeletal radiologists and pathologists, radiation oncologists, medical and pediatric oncologists, and microvascular surgeons.
  • [MeSH-minor] Global Health. Humans. Morbidity. Neoplasm Staging / methods. Prognosis

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18399615.001).
  • [ISSN] 0065-6895
  • [Journal-full-title] Instructional course lectures
  • [ISO-abbreviation] Instr Course Lect
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Number-of-references] 42
  •  go-up   go-down


12. Aydinli U, Ozturk C, Yalcinkaya U, Tirelioglu O, Ersozlu S: Limb-sparing surgery for primary malignant tumours of the pelvis. Acta Orthop Belg; 2004 Oct;70(5):417-22
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Limb-sparing surgery for primary malignant tumours of the pelvis.
  • Treatment of malignant tumours of the pelvis represents one of the most difficult problems in musculoskeletal oncology.
  • The aim of this paper is to present our results in 16 cases of primary malignant pelvic tumours following resection only or following reconstruction with autogenous or allogenous bone grafts without using megaprostheses, and to assess the possibility to restore acceptable function with autogenous or allogenous bone grafts while avoiding the high risks of massive endoprostheses.
  • Wound complication was the most common complication in our series, with 10 patients requiring additional treatment in the form of local surgical debridement, appropriate multi-drug antimicrobial therapy and wound care.
  • Major blood loss and long operation time, aggressive radical surgery due to the frequent delay in diagnosis, and wound complications after surgery are important points that should be considered in the treatment of primary malignant pelvic tumours.
  • [MeSH-minor] Adult. Angiography. Female. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Neoplasm Staging. Prognosis. Reconstructive Surgical Procedures / methods. Retrospective Studies. Risk Assessment. Sampling Studies. Survival Analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Bone Grafts.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15587029.001).
  • [ISSN] 0001-6462
  • [Journal-full-title] Acta orthopaedica Belgica
  • [ISO-abbreviation] Acta Orthop Belg
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Belgium
  •  go-up   go-down


13. Böhm P, Fritz J, Thiede S, Budach W: Reimplantation of extracorporeal irradiated bone segments in musculoskeletal tumor surgery: clinical experience in eight patients and review of the literature. Langenbecks Arch Surg; 2003 Jan;387(9-10):355-65
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Reimplantation of extracorporeal irradiated bone segments in musculoskeletal tumor surgery: clinical experience in eight patients and review of the literature.
  • We present our experience with the alternative reconstruction technique of reimplantating extracorporeally irradiated specimens (IEIR) PATIENTS AND METHODS: Eight patients who had primary malignant bone tumors of the long bones were managed with wide en bloc resection and IEIR.
  • All seven patients with high-grade tumors received chemotherapy.
  • One man with a chondroblastic osteosarcoma developed pulmonary metastases which were resected.
  • One woman with teleangiectatic osteosarcoma developed a local recurrence in the soft tissue without contact to the irradiated reimplant.
  • Another woman 67 months after IEIR for an osteosarcoma of the distal femur developed a subcutaneous metastasis of the scalp and the thoracic wall and an ossifying pulmonary metastasis.
  • At the time of writing she is receiving chemotherapy.

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Bone Grafts.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12536331.001).
  • [ISSN] 1435-2443
  • [Journal-full-title] Langenbeck's archives of surgery
  • [ISO-abbreviation] Langenbecks Arch Surg
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 46
  •  go-up   go-down


14. Van der Woude HJ, Egmont-Petersen M: Contrast-enhanced magnetic resonance imaging of bone marrow. Semin Musculoskelet Radiol; 2001;5(1):21-33
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This article discusses the characteristics of dynamic contrast-enhanced MR imaging of bone marrow edema, ischemia, and neoplasm.
  • It emphasizes its value in staging and in monitoring of response to chemotherapy of several bone tumors.
  • These fast dynamic contrast-enhanced techniques do not allow differentiation between benign and malignant primary osseous tumors because the biologic behavior rather than the malignant potential of these lesions is reflected.
  • [MeSH-minor] Bone Marrow Neoplasms / diagnosis. Bone Marrow Neoplasms / drug therapy. Bone Neoplasms / diagnosis. Bone Neoplasms / pathology. Edema / diagnosis. Gadolinium DTPA. Humans. Ischemia / diagnosis

  • MedlinePlus Health Information. consumer health - Bone Marrow Diseases.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • Hazardous Substances Data Bank. GADOPENTETATE DIMEGLUMINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11371333.001).
  • [ISSN] 1089-7860
  • [Journal-full-title] Seminars in musculoskeletal radiology
  • [ISO-abbreviation] Semin Musculoskelet Radiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Contrast Media; K2I13DR72L / Gadolinium DTPA
  •  go-up   go-down


15. Longhi A, Barbieri E, Fabbri N, Macchiagodena M, Favale L, Lippo C, Salducca N, Bacci G: Radiation-induced osteosarcoma arising 20 years after the treatment of Ewing's sarcoma. Tumori; 2003 Sep-Oct;89(5):569-72
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Radiation-induced osteosarcoma arising 20 years after the treatment of Ewing's sarcoma.
  • We report the case of a 17 years old female with a Ewing's sarcoma of the left femur treated with limb sparing surgery followed by local radiotherapy of 45 Gy and adjuvant chemotherapy with vincristine, doxorubicine, cyclophosphamide, actinomycin D.
  • The patient received neoadjuvant chemotherapy for osteosarcoma and a left femur resection with endoprosthesis replacement.
  • The patient is alive and free of disease 4 years after the treatment of this second malignant neoplasm (SMN).
  • This case shows that radioinduced SMN can occurr with relatively low doses of RT (<50 Gy) and that it may occur very late.
  • [MeSH-major] Bone Neoplasms / etiology. Bone Neoplasms / radiotherapy. Femur / radiation effects. Neoplasms, Second Primary / etiology. Osteosarcoma / etiology. Salvage Therapy. Sarcoma, Ewing / radiotherapy
  • [MeSH-minor] Adolescent. Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chemotherapy, Adjuvant. Female. Humans. Radiotherapy Dosage. Radiotherapy, Adjuvant / adverse effects. Time Factors. Treatment Outcome


16. Heare T, Hensley MA, Dell'Orfano S: Bone tumors: osteosarcoma and Ewing's sarcoma. Curr Opin Pediatr; 2009 Jun;21(3):365-72
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE OF REVIEW: Osteosarcoma and Ewing's sarcoma are the two most common primary malignant bone tumors in children and account for approximately 6% of all childhood malignancies.
  • Treatment methods have seen significant advancements, particularly in regard to chemotherapy and limb-sparing surgery.
  • With many long-term survivors, it is important to evaluate long-term patient outcomes following treatment, including function and health-related quality of life.
  • We will review the current trends in treatment of these diseases, different reconstructive options available, and the methods and results for evaluating the long-term results.
  • RECENT FINDINGS: There have been many improvements in the medical treatment of these tumors leading to increasing long-term survival.
  • Newer evaluation methods for both functional outcome and health-related quality of life measures that are more specific to children and adolescents are being developed and in use.
  • SUMMARY: This report will provide an overview of the current treatment options and long-term complications in primary malignant bone tumors for the pediatrician caring for a child with these problems.
  • [MeSH-minor] Adolescent. Child. Combined Modality Therapy. Humans. Morbidity. Neoplasm Staging / methods. United States / epidemiology

  • Genetic Alliance. consumer health - Ewing's Sarcoma.
  • Genetic Alliance. consumer health - Osteosarcoma.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19421061.001).
  • [ISSN] 1531-698X
  • [Journal-full-title] Current opinion in pediatrics
  • [ISO-abbreviation] Curr. Opin. Pediatr.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 57
  •  go-up   go-down


17. Wacnik PW, Kehl LJ, Trempe TM, Ramnaraine ML, Beitz AJ, Wilcox GL: Tumor implantation in mouse humerus evokes movement-related hyperalgesia exceeding that evoked by intramuscular carrageenan. Pain; 2003 Jan;101(1-2):175-86
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Importantly, using the grip force test, an assay of movement-related hyperalgesia, both non-malignant and malignant pain are examined in parallel.
  • Movement-related hyperalgesia, known clinically as a specific type of 'breakthrough pain', is a common feature of bone cancer and is thought to be a predictor of poor response to conventional analgesic pharmacotherapy (Bruera et al., 1995, J.
  • Control groups receiving implants of vehicle or no treatment at all did not manifest this forelimb hyperalgesia.
  • Tumor-implanted mice with a level of hyperalgesia comparable to that induced by carrageenan required almost three times more morphine (ED(50) 18.5mg/kg) for equivalent attenuation of forelimb hyperalgesia.
  • Importantly, they may also aid in predicting differences in analgesic efficacy in different types of musculoskeletal pain.
  • [MeSH-minor] Analgesics, Opioid / pharmacology. Animals. Carrageenan. Disease Models, Animal. Forelimb / physiology. Hand Strength. Humerus. Injections, Intramuscular. Male. Melanoma / complications. Melanoma / pathology. Mice. Mice, Inbred C3H. Morphine / pharmacology. Neoplasm Transplantation. Physical Stimulation. Skin

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. MORPHINE .
  • Hazardous Substances Data Bank. CARRAGEENAN GUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12507712.001).
  • [ISSN] 0304-3959
  • [Journal-full-title] Pain
  • [ISO-abbreviation] Pain
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / 1R01-CA84233-01A2; United States / NIDCR NIH HHS / DE / 5T 32-DEO 7288-02
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Analgesics, Opioid; 76I7G6D29C / Morphine; 9000-07-1 / Carrageenan
  •  go-up   go-down


18. Mankin HJ, Casas-Ganem J, Kim JI, Gebhardt MC, Hornicek FJ, Zeegen EN: Leiomyosarcoma of somatic soft tissues. Clin Orthop Relat Res; 2004 Apr;(421):225-31
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Leiomyosarcoma of somatic soft tissues.
  • Leiomyosarcoma is a rare, aggressively malignant connective tissue tumor of mature adults, which arises from smooth muscle.
  • It occurs most frequently in the uterus, bowel, vascular tissues, and less commonly in somatic soft tissue or bone.
  • The tumor when it arises in soft tissue has distinctive histologic features which somewhat resemble malignant fibrous histiocytoma (otherwise known as myxofibrosarcoma).
  • Factors that increase the death rate include size of the tumor, Musculoskeletal Tumor Society Stage of disease, and to a lesser extent particularly in the lower extremities, anatomic site.
  • Radiation and chemotherapy had little direct effect on the outcome but patients treated with surgery and adjunctive agents seemed to live longer than their cohorts treated with surgery alone.
  • The purpose of this study is a general review of the clinical and prognostic features of this cancer.
  • [MeSH-major] Leiomyosarcoma / mortality. Leiomyosarcoma / pathology. Soft Tissue Neoplasms / mortality. Soft Tissue Neoplasms / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Neoplasm Staging. Prognosis. Retrospective Studies. Survival Rate

  • Genetic Alliance. consumer health - Leiomyosarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15123952.001).
  • [ISSN] 0009-921X
  • [Journal-full-title] Clinical orthopaedics and related research
  • [ISO-abbreviation] Clin. Orthop. Relat. Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


19. Sumiya H, Taki J, Higuchi T, Tonami N: Nuclear imaging of bone tumors: thallium-201 scintigraphy. Semin Musculoskelet Radiol; 2001 Jun;5(2):177-82
MedlinePlus Health Information. consumer health - Bone Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Although the role for staging the disease of bone tumors and for differentiation of benign from malignant lesions is limited, (201)Tl scintigraphy reflects the disease activity after treatment and it should be used to determine the treatment response and for early diagnosis of recurrence.
  • Baseline study is essential for future reference to evaluate the response to preoperative chemotherapy and to detect recurrence after surgery.
  • Sequential (201)Tl scintigraphy before and after treatment is useful in assessing the grade of response of the tumor to chemotherapy.
  • The early prediction of chemotherapeutic effect by (201)Tl scintigraphy during treatment will affect the management of patients who do not respond to the therapy.
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Humans. Neoplasm Recurrence, Local / radionuclide imaging. Tomography, Emission-Computed, Single-Photon

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11500163.001).
  • [ISSN] 1089-7860
  • [Journal-full-title] Seminars in musculoskeletal radiology
  • [ISO-abbreviation] Semin Musculoskelet Radiol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Thallium Radioisotopes
  • [Number-of-references] 28
  •  go-up   go-down


20. Zhao H, Guo W, Peng C, Ji T, Lu X: Arsenic trioxide inhibits the growth of adriamycin resistant osteosarcoma cells through inducing apoptosis. Mol Biol Rep; 2010 Jun;37(5):2509-15
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Given that arsenic trioxide (As(2)O(3)) has been successfully used as a chemotherapeutic agent for refractory malignant tumors, this study is aimed at investigating the effect of As(2)O(3) on human Adriamycin resistant osteosarcoma cell line Saos-2.
  • The mechanism underlying multi drug resistance (MDR) in osteosarcoma cells and the anti-tumor effect of As(2)O(3) on Adriamycin resistant osteosarcoma cells were analyzed.
  • In our experiment, we first selected Adriamycin resistant osteosarcoma cell line by growing the classic osteosarcoma cell line Saos-2 in the medium with increasing drug concentrations.
  • Then, we compared the IC50s of the osteosarcoma cells treated with different anticancer drugs by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay.
  • Subsequently, we assessed the expression of classic MDR related molecules, Pgp, multidrug resistance-associated protein (MRP) and glutathione (GSH) activity in the wild type and Adriamycin resistant Saos-2 cells.
  • The study suggests that Adriamycin resistant osteosarcoma cells have good response to As(2)O(3)-based chemotherapy in vitro, probably via the pathway of inducing apoptosis.
  • [MeSH-major] Apoptosis / drug effects. Arsenicals / pharmacology. Doxorubicin / pharmacology. Drug Resistance, Neoplasm / drug effects. Osteosarcoma / pathology. Oxides / pharmacology
  • [MeSH-minor] Antineoplastic Agents / pharmacology. Apoptosis Regulatory Proteins / metabolism. Blotting, Western. Cell Line, Tumor. Cell Proliferation / drug effects. Drug Screening Assays, Antitumor. Glutathione / metabolism. Glutathione Transferase / metabolism. Humans. Inhibitory Concentration 50. Intracellular Space / drug effects. Intracellular Space / metabolism. Multidrug Resistance-Associated Proteins / metabolism

  • Genetic Alliance. consumer health - Osteosarcoma.
  • Hazardous Substances Data Bank. ARSENIC TRIOXIDE .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 2003 Aug 1;102(3):1028-34 [12676792.001]
  • [Cites] J Clin Oncol. 1991 Oct;9(10):1766-75 [1717666.001]
  • [Cites] Cancer Res. 1983 Nov;43(11):5286-92 [6225514.001]
  • [Cites] Cancer. 2003 May 1;97(9):2218-24 [12712474.001]
  • [Cites] Nat Rev Cancer. 2002 Apr;2(4):277-88 [12001989.001]
  • [Cites] Blood. 2003 May 15;101(10):4078-87 [12531793.001]
  • [Cites] Cancer Chemother Pharmacol. 2006 Dec;58(6):785-93 [16534613.001]
  • [Cites] Biochem Pharmacol. 1997 Jun 15;53(12):1855-66 [9256160.001]
  • [Cites] Anticancer Res. 1998 Jul-Aug;18(4C):3127-32 [9713521.001]
  • [Cites] Blood. 2004 May 1;103(9):3496-502 [14701702.001]
  • [Cites] Cancer Treat Rev. 2007 Oct;33(6):542-64 [17624680.001]
  • [Cites] Cancer Biother Radiopharm. 2007 Dec;22(6):772-8 [18158768.001]
  • [Cites] Cancer Res. 2004 Jan 1;64(1):108-16 [14729614.001]
  • [Cites] Cancer. 2003 Aug 1;98(3):581-9 [12879476.001]
  • [Cites] J Clin Oncol. 1998 Jul;16(7):2452-8 [9667263.001]
  • [Cites] Beijing Da Xue Xue Bao. 2007 Oct 18;39(5):467-71 [17940561.001]
  • [Cites] Anticancer Res. 2000 Mar-Apr;20(2B):1229-35 [10810426.001]
  • [Cites] J Biol Chem. 2004 Jul 30;279(31):32700-8 [15161912.001]
  • [Cites] Cancer. 1982 Mar 15;49(6):1221-30 [6174200.001]
  • [Cites] J Clin Oncol. 1992 Jan;10(1):5-15 [1370176.001]
  • [Cites] Int J Hematol. 2007 Jan;85(1):26-31 [17261498.001]
  • [Cites] Blood. 1999 Sep 15;94(6):2102-11 [10477740.001]
  • [Cites] Cancer Treat Rep. 1978 Feb;62(2):259-64 [346215.001]
  • [Cites] Hunan Yi Ke Da Xue Xue Bao. 2002 Apr 28;27(2):111-3 [12575332.001]
  • [Cites] Philos Trans R Soc Lond B Biol Sci. 2007 Jun 29;362(1482):959-71 [17317642.001]
  • [Cites] Horm Metab Res. 2003 Nov-Dec;35(11-12):786-93 [14710359.001]
  • [Cites] Hum Cell. 2001 Dec;14(4):305-15 [11925933.001]
  • [Cites] Haematologica. 2005 Sep;90(9):1231-5 [16154847.001]
  • [Cites] J Physiol Biochem. 2000 Dec;56(4):307-12 [11321524.001]
  • [Cites] Zhonghua Wai Ke Za Zhi. 2006 Jun 15;44(12):805-8 [16889724.001]
  • [Cites] Science. 1997 Feb 14;275(5302):983-6 [9020082.001]
  • (PMID = 19701692.001).
  • [ISSN] 1573-4978
  • [Journal-full-title] Molecular biology reports
  • [ISO-abbreviation] Mol. Biol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Apoptosis Regulatory Proteins; 0 / Arsenicals; 0 / Multidrug Resistance-Associated Proteins; 0 / Oxides; 80168379AG / Doxorubicin; EC 2.5.1.18 / Glutathione Transferase; GAN16C9B8O / Glutathione; S7V92P67HO / arsenic trioxide
  •  go-up   go-down


21. Gouin F, Ory B, Rédini F, Heymann D: Zoledronic acid slows down rat primary chondrosarcoma development, recurrent tumor progression after intralesional curretage and increases overall survival. Int J Cancer; 2006 Sep 1;119(5):980-4

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Chondrosarcoma is a difficult musculoskeletal tumor to treat.
  • Surgical treatment leads to severe disability, with high rates of local recurrence and life threat.
  • No adjuvant therapy is effective in differentiated chondrosarcomas.
  • Bisphosphonates (BPs) are a class of molecules which is effective in malignant bone diseases.
  • Two types of animal models were assessed, the first simulated development after intralesional curettage, the second nonoperative development of the tumor.
  • The present study demonstrates for the first time that in addition to surgery, the therapy of chondrosarcoma with BPs might be beneficial.
  • Because of these first results, new therapeutic approaches of chondrosarcoma must be considered, mainly for low grade chondrosarcoma when disabling operation is planned and when only intralesional resection can be undertaken.
  • [MeSH-major] Antineoplastic Agents / pharmacology. Bone Density Conservation Agents / pharmacology. Chondrosarcoma / drug therapy. Chondrosarcoma / surgery. Curettage. Diphosphonates / therapeutic use. Imidazoles / therapeutic use. Neoplasm Recurrence, Local / prevention & control
  • [MeSH-minor] Animals. Apoptosis / drug effects. Caspase 1 / metabolism. Caspase 3. Caspases / metabolism. Cell Cycle / drug effects. Cell Proliferation / drug effects. Chemotherapy, Adjuvant. Disease Progression. Male. Rats. Rats, Sprague-Dawley. Survival Analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2006 Wiley-Liss, Inc.
  • (PMID = 16570273.001).
  • [ISSN] 0020-7136
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Bone Density Conservation Agents; 0 / Diphosphonates; 0 / Imidazoles; 6XC1PAD3KF / zoledronic acid; EC 3.4.22.- / Casp3 protein, rat; EC 3.4.22.- / Caspase 3; EC 3.4.22.- / Caspases; EC 3.4.22.36 / Caspase 1
  •  go-up   go-down






Advertisement